Brought to you by:
Results from PROMISE II pivotal trial published, reinforcing ‘ transformational value’ of deep vein arterialization in no-option CLTI patients
Results from the PROMISE II pivotal trial investigating transcatheter arterialization of the deep veins using the LimFlow system in so-called no-option chronic limb-threatening ischemia (CLTI) patients were today published in the New England Journal of Medicine (NEJM). The publication confirmed…
DAPT linked to better post-TCAR outcomes versus other drug regimens
Dual antiplatelet therapy (DAPT) has demonstrated improved clinical outcomes, including reduced in-hospital stroke and mortality risks, compared to other medication regimens in carotid disease patients who undergo stent placement via a transcarotid artery revascularization (TCAR) procedure. This is the key…
SCVS 2023: Endovascular-first or -only approach to all CLTI patients ‘is not evidence-based care’
Michael S. Conte, MD, one of the foremost experts in the field of peripheral arterial disease (PAD), took attendees of the 2023 annual meeting of the Society for Clinical Vascular Surgery (SCVS) in Miami on a journey through the decades…
Short neck AAAs: ‘Choosing what is best for the patient’
Navigating cases of abdominal aortic aneurysm (AAA) with short neck anatomy poses a serious challenge to vascular surgeons, but the list of potential options available to carry out repairs are numerous—and decision-making can be optimized by using a bespoke algorithm.…
Pay SVS dues to receive SVS benefits, including VAM discount
With registration for the 2023 Vascular Annual Meeting (VAM) right around the corner, those people who have not paid their SVS 2023 dues have a good incentive to do so quickly. Members receive a discount on not only VAM but…
First US patient enrolled in Gore Viafort vascular stent pivotal study
W L Gore & Associates (Gore) has announced that the first U.S. patient has been enrolled in a prospective, randomized, multicenter, single-arm study with five-year follow-up to evaluate the investigational Gore Viafort vascular stent for the treatment of symptomatic inferior…
Getinge receives FDA premarket approval for the iCast covered stent system
Getinge‘s iCast covered stent system has received premarket approval from the Food and Drug Administration (FDA) for the treatment of patients with iliac arterial occlusive disease. The iCast covered stent system, sold outside the U.S. under the brand name Advanta…
Act now to keep CME credits, SVS urges members
Society for Vascular Surgery (SVS) members should act now so they do not lose earned continuing medical education (CME) credits. The American Board of Surgery (ABS) has changed its processes for CME credits, which affects their upload as well as…
Study highlights need for ‘continuous comparative assessments’ to guide endograft treatment decisions
A recent study comparing outcomes of endovascular aneurysm repair (EVAR) patients has reported no statistically significant differences in mortality or secondary rupture rates between standard Cook, Medtronic and Gore endografts, suggesting similar safety in a real-world setting. Michael O. Falster,…
STEVECO trial calls into question randomization in the venous stenting field
Recruitment proved to be a major challenge for the STEVECO (Stent versus conservative treatment in patients with deep venous obstruction) randomized controlled trial (RCT), prompting discussion on how best to randomize patients in future trials, the ethics of doing so,…